The decade-long saga capped by a $215,000 settlement with the US government

If you need a reminder of how slowly the wheels of justice grind, here’s one.

Earlier this month,  Sam W. Lee agreed to pay the U.S. government $215,000 to settle allegations that the former Harvard researcher had made false claims in a grant application.

It turns out that at least one skeptical researcher had notified journals and regulators about his concerns over the veracity of some of Lee’s other published findings back in 2011. 

In July of that year, David Vaux, an Australian scientist and research ethicist now at the Walter and Eliza Hall Institute of Medical Research in Melbourne, wrote to Nature about a new paper by Lee with what he believed were several critical flaws. According to Vaux, multiple colleagues of his had raised questions about the article, “Selective killing of cancer cells by a small molecule targeting the stress response to ROS,” which the journal had published earlier that month. 

Among the criticisms, wrote Vaux, a member of the board of directors of our parent non-profit organization, were: 

Continue reading The decade-long saga capped by a $215,000 settlement with the US government

False claims allegations cost Mass General, former Harvard researcher more than $1 million

A former Harvard researcher has agreed to pay $215,000 to settle allegations that he used bogus data in a grant application to the National Institutes of Health — and the teaching hospital where he worked has already repaid more than $900,000 in grant funds.

The settlement, of which we were just made aware, was announced on August 6,  six days before a lawyer for the researcher, Sam W. Lee, asked us to take down a post about his client’s problematic publications.

According to the U.S. Attorney’s Office for the District of Massachusetts, Lee knowingly made false claims when in June 2014 he submitted the “allegedly inauthentic data” as part of NIH grant R01 CA195534-01, titled “p53 survival target DDR1 kinase in DNA damage response and carcinogenesis”:

Continue reading False claims allegations cost Mass General, former Harvard researcher more than $1 million

Former Harvard cancer researcher faked a dozen images, say Feds

A cancer researcher faked a dozen images in three papers and a conference presentation while employed at Harvard teaching hospitals, according to a new report by a federal U.S. watchdog.

The Office of Research Integrity (ORI) found that David Panka

Continue reading Former Harvard cancer researcher faked a dozen images, say Feds

Duke group retracts Nature journal paper

A Nature journal is retracting a 2018 research letter about the genetics of flower patterns over concerns about the reliability of the data. 

The letter, “Two genetic changes in cis-regulatory elements caused evolution of petal spot position in Clarkia,” appeared in Nature Plants and was written by a team of researchers at Duke University, including Mark Rausher, a prominent plant geneticist and the John Carlisle Kilgo Professor of Biology at the institution. The paper has been cited 12 times, according to Clarivate Analytics’ Web of Science. 

Per the retraction notice

Continue reading Duke group retracts Nature journal paper

“Statins May Cut Glaucoma Risk,” said a New York Times headline. But is that true?

via Flickr

Last year, JAMA Ophthalmology published a study that claimed to find a link between using cholesterol-lowering drugs known as statins and a reduced risk of glaucoma. In a New York Times story on the paper, lead author

Jae H. Kang, an assistant professor of medicine at Brigham and Women’s Hospital in Boston, suggested that statins reduce pressure in the eye, help maintain good blood flow and may help protect the optic nerve.

But Kang came to realize, while reviewing the results for another study, that her research had a major error, as she writes in a letter accompanying the retraction and replacement of the study. Kang tells Retraction Watch:

Continue reading “Statins May Cut Glaucoma Risk,” said a New York Times headline. But is that true?

Fourth retraction for Haruko Obokata, focus of STAP cell scandal, after Harvard investigation

Charles Vacanti

More than five years after Nature retracted two highly suspect papers about what had been described as a major breakthrough in stem cell research, another journal has pulled a paper about the work. 

The scandal over so-called STAP stem cells took down more than just a few articles. The case centered on Haruko Obokata, a Japanese researcher who conducted the studies as a post-doc in the Harvard lab of Charles Vacanti. Obokata lost her doctoral thesis from Waseda University in 2015 because it plagiarized from the U.S. National Institutes of Health. She also retracted a paper in Nature Protocols

Continue reading Fourth retraction for Haruko Obokata, focus of STAP cell scandal, after Harvard investigation

Harvard group retracts Nature paper

via Wikimedia

A group of researchers based at Harvard University have retracted an influential 2017 letter in Nature after a change in lab personnel led to the discovery of errors in the analysis. 

The article, “Microglia-dependent synapse loss in type I interferon-mediated lupus,” emerged from a collaboration including scientists at Harvard Medical School, the Rockefeller University in New York City, the University of Magdeburg, in Germany. 

The senior author of the research letter — which has been cited 75 times, earning it a highly cited designation from Clarivate Analytics’ Web of Science — was Michael C. Carroll, a prominent immunology researcher. [See disclosure at the end of this post.] Also on the list was Ronald Herbst, who at the time was vice president of research at MedImmune but has since left that company for another biotech firm. The first author was Allison Bialas, at the time a post-doc at Harvard. 

According to the abstract: 

Continue reading Harvard group retracts Nature paper

Duke misconduct case prompts another expression of concern — but not a retraction

The Duke Chapel

Here’s an expression of concern that raised some eyebrows around the Retraction Watch HQ.

Continue reading Duke misconduct case prompts another expression of concern — but not a retraction

NIH to lift Duke sanctions stemming from misconduct

Duke University

The U.S. National Institutes of Health (NIH) plans to lift sanctions it placed on Duke University more than 1.5 years ago following concerns about how the school responded to recent cases of misconduct.

In a memo today to faculty and staff obtained by Retraction Watch, Lawrence Carin, Duke vice president for research wrote:

Continue reading NIH to lift Duke sanctions stemming from misconduct

Cancer lab at Harvard subject of inquiry

James Mier

Harvard has investigated work from the lab of a cancer researcher at Beth Israel Deaconess Medical Center that has been under scrutiny on PubPeer for more than five years.

Questions about the output of the lab, run by James W. Mier, began appearing on PubPeer in 2014, with comments about images that looked manipulated. The pseudonymous whistleblower Clare Francis sent Gretchen Brodnicki, Harvard Medical School’s dean for faculty and research integrity, an email about those comments on Sept. 27, 2014, and on July 24 of this year, Brodnicki asked Francis to resend that email.

Also that month, the journal Clinical Cancer Research issued an expression of concern for a 2006 paper by Mier and colleagues, which stated:

Continue reading Cancer lab at Harvard subject of inquiry